AAV-mediated peripheral single chain variable fragments administration to reduce cerebral tau in adult P301S transgenic mice: mono- vs combination therapy
Katel, S.; Cicalo, J.; Vasciaveo, V.; Carrion, J.; Mahadeo, L.; Huerta, P. T.; Marambaud, P.; Giliberto, L.; d'Abramo, C.
Show abstract
Tau is a primary target for immunotherapy in Alzheimers disease. Recent studies have shown the potential of anti-tau fragment antibodies in lowering pathological tau levels in vitro and in vivo. Here, we compared the effects of single-chain variable fragments (scFv) derived from the well-characterized monoclonal antibodies PHF1 and MC1. We used adeno-associated virus 1 (AAV1) to deliver scFvs to skeletal muscle cells in eight-week-old P301S tau transgenic mice. We evaluated motor and behavioral functions at 16 and 23 weeks of age and measured misfolded, soluble, oligomeric and insoluble brain tau species. Monotherapy with scFv-MC1 improved motor and behavioral functions more effectively than scFv-PHF1 or combination therapy. Brain glucose metabolism also benefited from scFv-MC1 treatment. Surprisingly, combining scFvs targeting early (MC1) and late (PHF1) tau modifications did not produce additive or synergistic effects. These results confirm that intramuscular AAV1-mediated scFv-MC1 gene therapy holds promise as a potential treatment for Alzheimers disease. Our findings also suggest that combining scFvs targeting different tau epitopes may not necessarily enhance efficacy if administered together in a prevention paradigm. Further research is needed to explore whether other antibodies combinations and/or administration schedules could improve the efficacy of scFv-MC1 alone. Graphical abstract/eTOC synopsisKatel and colleagues show that peripheral vectorized scFvMC1 (in monotherapy) reduces pathological tau species in tau transgenic mice more efficiently than in combination with scFv-PHF1. The authors observed improved motor and behavioral functions together with increased brain glucose metabolism in scFv-MC1-treated mice. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=136 SRC="FIGDIR/small/638144v1_ufig1.gif" ALT="Figure 1"> View larger version (35K): org.highwire.dtl.DTLVardef@7edcccorg.highwire.dtl.DTLVardef@d1fc50org.highwire.dtl.DTLVardef@bf6f8org.highwire.dtl.DTLVardef@1832331_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 13 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Amyloid plaque deposition accelerates tau propagation via activation of microglia in a humanized APP mouse model 96%
- SETD7-mediated lysine monomethylation is abundant on non-hyperphosphorylated nuclear Tau 95%
- Diabetic phenotype in mouse and humans with β-amyloid pathology reduces the number of microglia around β-amyloid plaques 95%
Similar papers in this journal
- APOE2 gene therapy reduces amyloid deposition, and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease 95%
- The unfolded protein response transcription factor XBP1s ameliorates Alzheimer`s disease by improving synaptic function and proteostasis 95%
- Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment 94%
Similar papers in this journal
Similar papers in this journal
- Tau seeding and spreading in vivo is supported by both AD-derived fibrillar and oligomeric tau 96%
- TMEM106B coding variant is protective and deletion detrimental in a mouse model of tauopathy 96%
- Tau phosphorylated at serine 356 is associated with Alzheimer's disease pathology and can be lowered in mouse and human brain tissue using the NUAK inhibitor WZ4003 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.